VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTGN VistaGen Therapeutics, Inc.

未开盘 10-29 16:00:00 EDT

0.1707

+0.0007

+0.41%

盘后0.1741

+0.0034+1.99%

19:55 EDT

最高0.1736	最低0.1667	成交量52.27万
今开0.1667	昨收0.1700	日振幅4.06%
总市值757.51万	流通市值707.09万	总股本4,438万
成交额8.89万	换手率1.26%	流通股本4,142万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTGN","market":"US","secType":"STK","nameCN":"VistaGen Therapeutics, Inc.","latestPrice":0.1707,"timestamp":1793304000000,"preClose":0.17,"halted":0,"volume":522674,"hourTrading":{"tag":"盘后","latestPrice":0.1741,"preClose":0.1707,"latestTime":"19:55 EDT","volume":14186,"amount":2453.8053,"timestamp":1793318152123,"change":0.0034,"changeRate":0.019918,"amplitude":0.019918},"delay":0,"changeRate":0.004117647058823402,"floatShares":41422900,"shares":44376899,"eps":-1.655879,"marketStatus":"未开盘","change":0.0007,"latestTime":"10-29 16:00:00 EDT","open":0.1667,"high":0.1736,"low":0.1667,"amount":88885.58502168,"amplitude":0.040588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.655879,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793347200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1462939200000,"exchange":"NASDAQ","adjPreClose":0.17,"preHourTrading":{"tag":"盘前","latestPrice":0.17,"preClose":0.17,"latestTime":"09:13 EDT","volume":24703,"amount":4005.75473683,"timestamp":1793279637388,"change":0,"changeRate":0,"amplitude":0.058824},"postHourTrading":{"tag":"盘后","latestPrice":0.1741,"preClose":0.1707,"latestTime":"19:55 EDT","volume":14186,"amount":2453.8053,"timestamp":1793318152123,"change":0.0034,"changeRate":0.019918,"amplitude":0.019918},"volumeRatio":0.604381,"impliedVol":3.512,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/VTGN","defaultTab":"news","newsList":[{"id":"1180920255","title":"VistaGen Therapeutics：不良事件停药率仅为1.6%，且无一例归因于Fasedienol","url":"https://stock-news.laohu8.com/highlight/detail?id=1180920255","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180920255?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:32","pubTimestamp":1790080329,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics公布最新数据——因不良事件导致的停药率仅有1.6%，更值得关注的是，所有病例均未归因于Fasedienol的使用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107460138","title":"Vistagen Therapeutics：Fasedienol鼻喷雾剂12个月耐受性良好，无新增药物相关安全性问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1107460138","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107460138?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:31","pubTimestamp":1790080282,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics公司近日公布了其Fasedienol鼻喷雾剂的长期安全性数据。结果显示，经过整整12个月的持续使用，该药物表现出良好的耐受性，且未出现任何新的、与药物相关的安全性发现。这一积极成果为这款在研疗法增添了重要的安全佐证。从临床开发的角度看，这种长期安全性数据对于监管审评和后续商业化都至关重要。Vistagen Therapeutics正稳步推进其管线，而这一里程碑式的安全性数据，无疑为其未来的临床路径铺设了更为坚实的基石。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123980795","title":"Vistagen公布Fasedienol治疗社交焦虑障碍Palisade-4三期临床研究开放标签扩展部分初步积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123980795","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123980795?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:31","pubTimestamp":1790080272,"startTime":"0","endTime":"0","summary":"Vistagen今日宣布，其在研药物Fasedienol用于社交焦虑障碍急性治疗的关键性Palisade-4三期临床研究，其开放标签扩展部分已取得初步积极数据。公司表示，来自扩展阶段的研究结果进一步佐证了Fasedienol在先前已报道的安慰剂对照部分所展现出的疗效与安全性特征。Palisade-4研究是一项设计严谨、规模可观的三期临床试验，旨在全面评估Fasedienol在社交焦虑障碍患者急性症状管理中的潜力。而此次公布的开放标签扩展阶段数据，则为长期用药的安全性及耐受性提供了有价值的补充证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192497743","title":"VistaGen第一财季每股亏损0.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192497743","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192497743?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:43","pubTimestamp":1786711410,"startTime":"0","endTime":"0","summary":"生物制药公司VistaGen Therapeutics公布了其第一财季业绩，数据显示，公司净亏损达到1303万美元，折合每股亏损0.30美元。这一财务表现反映出公司在研发投入与运营成本上的持续支出，而尚未实现盈利。尽管市场对其治疗领域的前景存在期待，但当前财报显示，该公司仍处于亏损扩张阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132595340","title":"Vistagen公布Fasedienol重复剂量研究用于社交焦虑症急性治疗的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132595340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132595340?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:36","pubTimestamp":1786019767,"startTime":"0","endTime":"0","summary":"Vistagen（VistaGen Therapeutics）今日宣布，其针对Fasedienol用于社交焦虑障碍急性治疗的重复剂量研究，已达到顶线结果。此项研究旨在评估药物有效性及安全性，为后续临床开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117897766","title":"Vistagen Therapeutics 旗下Fasedienol在主要与次要终点均展现疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1117897766","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117897766?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:33","pubTimestamp":1786019597,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics公布了一项积极进展：其核心药物Fasedienol在临床试验中，于主要终点及次要终点均观察到了明确的疗效信号。这一发现为这一候选疗法增添了新的希望，也标志着公司在焦虑症治疗领域迈出了关键一步。该疗效信号的显现，意味着药物不仅在预设的主要评估指标上表现突出，还在一系列辅助性指标上同步验证了其治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189830212","title":"Vistagen Therapeutics：法西地诺重复给药展现与单次给药相当的安全性及耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1189830212","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189830212?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:31","pubTimestamp":1786019481,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics 公司宣布，其核心药物法西地诺（Fasedienol）在重复给药试验中，表现出与单次给药同样良好的安全性与耐受性。这一发现，为这款候选药物的后续开发提供了关键性支持。无论是单次应用还是多次给药，法西地诺均未引发显著差异的不良反应，其耐受性特征保持高度一致。这意味着，在反复用药的场景下，该药物的安全性轮廓并未出现意料之外的恶化。对于Vistagen Therapeutics而言，这无疑是一个积极信号。它进一步巩固了法西地诺作为一种潜在治疗选择的地位，特别是在那些需要长期或周期性用药的适应症领域。目前，公司正基于这些数据，积极推进后续的临床研究计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122815029","title":"Vistagen Therapeutics 在重度社交焦虑症患者中显示出名义上的统计显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1122815029","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122815029?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:31","pubTimestamp":1786019480,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics 公布了一项临床研究结果，针对重度社交焦虑症患者，该公司疗法展现出名义上的统计显著改善。这一数据为治疗这类严重心理障碍领域带来了新的希望。尽管改善幅度被标记为“名义上”显著，但依然凸显了潜在的治疗价值。患者群体处于病情严重状态，任何积极信号都值得关注。VistaGen Therapeutics 正致力于推进其核心管线，探索更有效的干预方案。此次发现无疑增强了市场对其研发方向的预期。然而，后续还需更大规模验证，以确认疗效的稳定性与临床意义。整体来看，这一进展传递出积极信号，但距离实际应用仍有关键节点待突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106146048","title":"VistaGen公布Fasedienol治疗社交焦虑症的Palisade-4三期公众演讲挑战试验顶线及事后分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1106146048","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106146048?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:26","pubTimestamp":1783322808,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics Inc.宣布了其候选药物Fasedienol用于社交焦虑症急性治疗的Palisade-4三期公众演讲挑战试验的顶线结果及事后分析数据。试验数据显示，Fasedienol在主要和次要终点上均未达到统计学意义上的显著改善。\n然而，该药物的安全性和耐受性数据良好，与先前的临床试验结果保持一致。\n公司计划与美国食品药品监督管理局（FDA）会面，就Fasedienol的未来三期试验及注册路径进行讨论。\n值得注意的是，一项事后分析表明，在非常严重的社交焦虑症患者亚组中，Fasedienol显示出名义上的统计学显著性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142107877","title":"VistaGen公司事后分析显示，Fasedienol在极重度社恐亚组中达到名义统计显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1142107877","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142107877?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:03","pubTimestamp":1782821010,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics 公布的一项事后分析结果显示，其候选药物 Fasedienol 在针对极重度社交焦虑障碍亚组患者的研究中，达到了名义上的统计学显著性。该分析聚焦于病情程度最为严重的患者群体，数据显示，与安慰剂相比，Fasedienol 在这一特定亚组中展现出具有前景的疗效信号。名义统计显著性意味着，在未对多重检验进行调整的情况下，结果达到了预设的统计阈值。这一发现为 Fasedienol 的后续临床开发路径提供了新的见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128069424","title":"VistaGen公布Fasedienol治疗社交焦虑障碍急性期Palisade-4三期公开演讲挑战试验的顶线及事后分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1128069424","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128069424?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820910,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics, Inc. (VTGN) 公布了其候选药物Fasedienol用于社交焦虑障碍急性期治疗的三期临床试验Palisade-4的顶线数据及事后分析结果。该试验采用公开演讲挑战模型进行评估。\n数据显示，在主要终点和关键次要终点上，Fasedienol治疗组与安慰剂组相比，未达到统计学显著性差异。然而，公司进行的探索性事后分析指出，在预先设定的亚组人群中观察到了具有临床意义的改善信号。\n此次公布的数据为后续临床开发策略提供了重要参考。公司表示将继续深入分析完整数据集，以进一步明确Fasedienol的潜在治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150037136","title":"VistaGen Therapeutics公司：Fasedienol在主要及次要终点上未实现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1150037136","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150037136?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820902,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics, Inc. (VTGN) 近日公布，其候选药物Fasedienol在关键临床试验中，未能于主要及次要疗效终点上展现出统计学意义上的显著改善。这一结果标志着该药物在特定治疗路径上遭遇了重大挫折，引发了市场对公司研发管线进展的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168620088","title":"VistaGen计划与FDA会晤，探讨Fasedienol的注册路径及未来三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1168620088","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168620088?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820900,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics公司宣布，计划与美国食品药品监督管理局（FDA）会面，商讨其候选药物Fasedienol的注册申报路径以及未来的三期临床试验规划。此次会议旨在为后续的临床开发与监管提交确定清晰的路线图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109937075","title":"VistaGen Therapeutics公布积极安全性及耐受性数据 与既往临床试验结果一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1109937075","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109937075?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820894,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics披露的最新数据显示，其药物在安全性及耐受性方面的表现令人鼓舞，这一结果与先前开展的临床试验所得结论高度吻合。该积极数据进一步巩固了公司研发管线的可靠性，为后续的临床开发路径提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114884667","title":"VistaGen Therapeutics, Inc. 旗下Fasedienol鼻喷雾剂耐受性良好，12个月后无新增安全性发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1114884667","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114884667?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:31","pubTimestamp":1778585476,"startTime":"0","endTime":"0","summary":"VistaGen Therapeutics, Inc. 宣布，其Fasedienol鼻喷雾剂在为期12个月的观察期内展现出良好的耐受性，未发现新的安全性问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172520288","title":"Vistagen披露Palisade-3三期研究开放标签扩展部分初步积极数据，Fasedienol用于社交焦虑障碍急性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1172520288","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172520288?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:31","pubTimestamp":1778585475,"startTime":"0","endTime":"0","summary":"Vistagen公司宣布，在其Palisade-3三期研究中，关于Fasedienol用于社交焦虑障碍急性治疗的开放标签扩展部分，获得了初步的积极数据。这项研究目前仍在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143674821","title":"VistaGen Therapeutics第三季度每股收益$(0.46)超出预期$(0.51)，销售额23.4万美元超出预期18万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143674821","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143674821?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:44","pubTimestamp":1739483087,"startTime":"0","endTime":"0","summary":"与去年同期的每股亏损$相比，这是109.09%的下降。公司报告季度销售额为23.4万美元，超出分析师一致预期的18万美元，高出30%。与去年同期的41.14万美元相比，这一数据下降了43.12%。以上内容来自Benzinga Earnings专栏，原文如下：VistaGen $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 9.8 percent. This is a 109.09 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent.  This is a ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"VistaGen Therapeutics第三季度每股收益$(0.46)超出预期$(0.51)，销售额23.4万美元超出预期18万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507467790","title":"Vistagen Therapeutics, Inc.盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507467790","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507467790?lang=zh_cn&edition=full","pubTime":"2025-01-31 04:05","pubTimestamp":1738267529,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日04时05分，Vistagen Therapeutics, Inc.股票出现波动，股价大幅上涨5.59%。截至发稿，该股报3.02美元/股，成交量7.4433万股，换手率0.27%，振幅6.56%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Dominari Holdings Inc.涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1808.61%、328.29%、253.64%，振幅较大的相关个股有Dominari Holdings Inc.、Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为70.55%、65.98%、64.10%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310405299876d5ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310405299876d5ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTGN","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504816292","title":"Vistagen Therapeutics, Inc.盘中异动 股价大涨6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504816292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504816292?lang=zh_cn&edition=full","pubTime":"2025-01-17 22:32","pubTimestamp":1737124343,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日22时32分，Vistagen Therapeutics, Inc.股票出现波动，股价快速上涨6.16%。截至发稿，该股报3.10美元/股，成交量1.0667万股，换手率0.04%，振幅6.16%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Channel Therapeutics Corporation、Immuron Limited、Revance Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Aeon Biopharma, Inc.、Bioline Rx Ltd较为活跃，换手率分别为92.11%、14.24%、6.82%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、天境生物、Jupiter Neurosciences, Inc.，振幅分别为25.26%、10.00%、9.84%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223223a225bc25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223223a225bc25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","VTGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2487256146","title":"Vistagen Therapeutics, Inc.盘中异动 早盘快速拉升5.20%报2.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487256146","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2487256146?lang=zh_cn&edition=full","pubTime":"2024-11-30 00:26","pubTimestamp":1732897566,"startTime":"0","endTime":"0","summary":"北京时间2024年11月30日00时26分，Vistagen Therapeutics, Inc.股票出现异动，股价大幅拉升5.20%。截至发稿，该股报2.83美元/股，成交量4.018万股，换手率0.14%，振幅5.76%。Vistagen Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Passage Bio, Inc.涨幅较大，Silo Pharma, Inc.、Klotho Neurosciences, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为176.47%、70.13%、62.72%，振幅较大的相关个股有Cingulate Inc C/Wts 10/12/2026 、Klotho Neurosciences, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为130.29%、105.44%、68.75%。Vistagen Therapeutics, Inc.公司简介：VistaGen Therapeutics Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024113000260698e46ad5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024113000260698e46ad5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VTGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vistagen.com","stockEarnings":[{"period":"1week","weight":-0.1219},{"period":"1month","weight":-0.4276},{"period":"3month","weight":-0.2946},{"period":"6month","weight":-0.7283},{"period":"1year","weight":-0.958},{"period":"ytd","weight":-0.7432}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vistagen Therapeutics, Inc.于1998年5月26日注册成立。该公司是一家处于临床后期阶段的治疗公司，专注于开发用于社交焦虑症、抑郁症、更年期潮热、精神疲劳引起的精神运动障碍以及癌症恶病质的药物。其管线包括鼻内给予的pherine候选产品，设计用于结合鼻腔化学感觉神经元中的外周受体，并在无需全身吸收的情况下激活调节脑区的神经回路。最领先的候选产品fasedienol正在美国进行社交焦虑症的3期临床项目。其他候选产品包括用于抑郁症的itruvone、用于更年期潮热的refisolone、用于精神运动障碍的PH15以及用于癌症恶病质的PH284。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.126859},{"month":2,"riseRate":0.3,"avgChangeRate":-0.102734},{"month":3,"riseRate":0.2,"avgChangeRate":-0.108038},{"month":4,"riseRate":0.6,"avgChangeRate":0.018256},{"month":5,"riseRate":0.6,"avgChangeRate":0.003251},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.136963},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.018242},{"month":8,"riseRate":0.818182,"avgChangeRate":0.24982},{"month":9,"riseRate":0.363636,"avgChangeRate":0.048795},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.09678},{"month":11,"riseRate":0.4,"avgChangeRate":-0.060004},{"month":12,"riseRate":0.7,"avgChangeRate":0.164554}],"exchange":"NASDAQ","name":"VistaGen Therapeutics, Inc.","nameEN":"VistaGen Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供VistaGen Therapeutics, Inc.(VTGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"VistaGen Therapeutics, Inc.,VTGN,VistaGen Therapeutics, Inc.股票,VistaGen Therapeutics, Inc.股票老虎,VistaGen Therapeutics, Inc.股票老虎国际,VistaGen Therapeutics, Inc.行情,VistaGen Therapeutics, Inc.股票行情,VistaGen Therapeutics, Inc.股价,VistaGen Therapeutics, Inc.股市,VistaGen Therapeutics, Inc.股票价格,VistaGen Therapeutics, Inc.股票交易,VistaGen Therapeutics, Inc.股票购买,VistaGen Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VistaGen Therapeutics, Inc.(VTGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供VistaGen Therapeutics, Inc.(VTGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}